Yes, there will be more investor/analyst interest in the ADXS-NEO program once it starts dosing patients. ADXS' generally poor reputation is also a factor (IMO), as compared to some of the other companies (public and private) who are pursuing neoantigen cancer vaccines.
Some are. Although not mentioned in the Nature article, ADRO is another neoantigen company ahead of ADXS on timing (#msg-134949543).